Menu
Search
|

Menu

Close
X

Agile Therapeutics Inc AGRX.OQ (NASDAQ Stock Exchange Global Market)

0.58 USD
-- (--)
As of Jun 20
chart
Previous Close 0.58
Open --
Volume --
3m Avg Volume 70,408
Today’s High --
Today’s Low --
52 Week High 5.59
52 Week Low 0.54
Shares Outstanding (mil) 34.25
Market Capitalization (mil) 19.80
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.33 Mean rating from 6 analysts

KEY STATS

Revenue (mm, USD)
FY18
0
FY17
0
FY16
0
FY15
0
EPS (USD)
FY18
-0.200
FY17
-0.924
FY16
-1.018
FY15
-1.381
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
33.88
Price to Sales (TTM)
vs sector
--
8.30
Price to Book (MRQ)
vs sector
0.65
4.32
Price to Cash Flow (TTM)
vs sector
--
22.70
Total Debt to Equity (MRQ)
vs sector
29.70
17.35
LT Debt to Equity (MRQ)
vs sector
0.00
12.89
Return on Investment (TTM)
vs sector
-73.04
13.21
Return on Equity (TTM)
vs sector
-83.42
15.18

EXECUTIVE LEADERSHIP

Alfred Altomari
Chairman of the Board, President, Chief Executive Officer, Since 2016
Salary: $362,500.00
Bonus: $160,000.00
Scott Coiante
Chief Financial Officer, Vice President, Since 2011
Salary: $250,000.00
Bonus: $76,300.00
Elizabeth Garner
Senior Vice President, Chief Medical Officer, Since 2014
Salary: $315,960.00
Bonus: $108,000.00
Renee Selman
Chief Commercial Officer, Since 2016
Salary: --
Bonus: --
Abhijeet Lele
Lead Independent Director, Since 2016
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

101 Poor Farm Rd
PRINCETON   NJ   08540-1941

Phone: +1609.6831880

Agile Therapeutics, Inc. is a women's health specialty pharmaceutical company. The Company is focused in the development and commercialization of prescription contraceptive products. The Company has developed a transdermal patch technology, called Skinfusion. The Company's lead product candidate is Twirla, also known as AG200-15, is a combined hormonal contraceptive (CHC) patch. In addition to Twirla, the Company is developing a pipeline of other new transdermal contraceptive products, including AG200-ER, which is a regimen designed to allow a woman to extend the length of her cycle; AG200-SP, which is a regimen designed to provide a shortened hormone-free interval, and AG890, which is a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen. Each of its product candidates utilizes its Skinfusion technology designed to deliver contraceptive-levels of hormones to the blood stream through the skin over a seven-day period.

SPONSORED STORIES